ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology.
Poster presentations will be accessible to both live and virtual meeting attendees starting at 5:00 p.m. Central time on Friday, October 21, 2022. Posters can be viewed through the Conference Planner and MyASTROApp, and in the Virtual Poster Library.
To view posters in the Virtual Poster Library, you will be asked to create an account. The library is not tied to your ASTRO.org account. If you created a login for past ASTRO meetings, you can use that login information again.
Visit the Poster Hall to peruse posters at your own pace. The Poster Hall is located in Hall 1, and can be accessed through the Exhibit Hall, or through a door off the main lobby when the Exhibit Hall is closed.
| Date |
Time |
| Sunday, October 23 |
10:00 a.m. - 6:00 p.m. |
| Monday, October 24 |
8:45 a.m. - 6:00 p.m. |
| Tuesday, October 25 |
8:45 a.m. - 6:15 p.m. |
| Wednesday, October 26 |
8:45 a.m. - 1:45 p.m. |
During scheduled times, attendees will have the opportunity to ask poster presenters questions about their research. Posters will be organized by track, as outlined below. View the Poster Q&A presentation schedule below for specific times.
The Poster Q&A Session Schedule is outlined below:
Sunday, October 23, 2022
| Session |
Time |
Tracks/Group |
| Poster Session 1 |
4:45 p.m. - 6:00 p.m. |
Lung Cancer/Thoracic Malignancies
Diversity, Equity and Inclusion in Health Care |
Monday, October 24, 2022
| Session |
Time |
Tracks/Group |
| Poster Session 2 |
10:45 a.m. - 12:00 p.m. |
Central Nervous System
Palliative Care |
| Poster Session 3 |
3:00 p.m. - 4:00 p.m. |
Breast Cancer
Nonmalignant Disease |
| Poster Session 4 |
5:00 p.m. - 6:00 p.m. |
Radiation and Cancer Biology
Patient Reported Outcomes/QoL/Survivorship |
Tuesday, October 25, 2022
| Session |
Time |
Tracks/Group |
| Poster Session 5 |
12:45 p.m. - 2:00 p.m. |
Gastrointestinal Cancer
Sarcoma and Cutaneous Tumors |
| Poster Session 6 |
2:30 p.m. - 3:45 p.m. |
Genitourinary Cancer
Patient Safety
Nursing and Supportive Care |
| Poster Session 7 |
4:00 p.m. - 5:00 p.m. |
Digital Health Innovation
Hematologic Malignancies |
| Poster Session 8 |
5:15 p.m. - 6:15 p.m. |
Gynecological Cancer
Pediatric Cancer
Professional Development/Medical Education |
Wednesday, October 26, 2022
| Session |
Time |
Tracks/Group |
| Poster Session 9 |
10:30 a.m. - 11:45 a.m. |
Head and Neck Cancer
Health Services Research/Global Oncology |
| Poster Session 10 |
12:30 p.m. - 1:45 p.m. |
Radiation and Cancer Physics |
Live virtual meeting attendees will not be able to participate in Poster Q&A Sessions. However, this does not mean that virtual attendees will miss out on hearing all about this important research! Each poster author will add audio narration to their poster, which virtual meeting attendees will be able to listen to through the virtual poster library, as well as in the Conference Planner and in the MyASTROApp.
To view posters in the Virtual Poster Library, you will be asked to create an account. The library is not tied to your ASTRO.org account. If you created a login for past ASTRO meetings, you can use that login information again.
ASTRO is bringing back Poster Walks reimagined! Poster Walks will coincide with Poster Q&A Sessions. During each session, an expert in the field will lead meeting attendees through the poster hall to view a curated selection of posters in each disease site. Poster Q&A Sessions features up to 150 posters in each track, so these Poster Walks give meeting attendees the opportunity to view a smaller collection of posters that more closely align with their interests. Attendees will listen to poster authors present their research, and have the opportunity to ask questions.
Meeting attendees do not sign up for the poster walk ahead of time. Instead, interested participants will meet Poster Walk leaders at the Concierge Desk in Exhibit Hall 1 before the start of the Poster Q&A Session
This event is a great opportunity for residents, early career radiation oncologists and first-time meeting attendees, giving them the opportunity to interface directly with poster authors and network with colleagues.
Poster Walk 1: Lung Cancer
Sunday, October 23, at 4:45 - 6:00 pm CT
| Leader |
Jason Ye, MD |
| Location |
Screen 1 |
| Abstracts |
High-Dose Spatially Fractionated Radiotherapy, Lattice Radiotherapy in Bulky Tumors: Results after One Year Follow-Up
Whole Tumor vs. FDG-Directed Dose Escalation in Patients with Locally Advanced NSCLC: Evaluation of Isotoxic Treatment Plans from the Randomized ARTFORCE PET-Boost Trial
Widening the Therapeutic Window for Central and Ultra-Central Thoracic Oligometastatic Disease with Stereotactic MR-Guided Adaptive Radiation Therapy (SMART)
Prognostic Image Biomarkers in the Treatment of Patients with Locally Advanced NSCLC
Dynamic Change of Indoleamine 2,3-Dioxygenase Activity Predicts Survival in Radiotherapy-Received Unresectable Stage III NSCLC
|
| Leader |
Greg Videtic, MD, FASTRO, CM, FRPC, FACR |
| Location |
Screen 8 |
| Abstracts |
Toxicity of Single-Fraction SABR for Non-Small Cell Lung Cancer
Real World Practice of Postoperative Radiotherapy for Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer
Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-Small Cell Lung Cancer: A Phase I/II Clinical Trial
Patterns of Failure in Resectable Stage I-IIIA NSCLC Treated with Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial
Mediastinal and Hilar Lymphadenopathy Treated by SABR
|
| Leader |
Nitin Ohri, MD, MS |
| Location |
Screen 18 |
| Abstracts |
Association of Skeletal Muscle Area with Toxicity and Treatment Tolerance in Patients Receiving Chemoradiation for Advanced Lung CancerIncreasing Radiation Dose in the Setting of Treatment Prolongation for Stage III Non-Small Cell Lung Cancer (NSCLC)
Evaluating Radiation-Related Risk Factors for Pneumonitis in Patients with Stage III NSCLC Receiving Durvalumab after Definitive Chemoradiation
Tumor Mutational Burden Predicts Progression-Free Survival and Local-Regional Control in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Durvalumab
Salvage Re-Irradiation with Proton Beam Therapy for New or Locoregionally Recurrent Non-Small Cell Lung Cancer
|
Poster Walk 2: Central Nervous System
Monday, October 24, at 10:45 am - 12:00 pm CT
| Leader |
Joshua Palmer, MD |
| Location |
Screen 18 |
| Abstracts |
To Come |
Poster Walk 3: Breast Cancer
Monday, October 24, at 3:00 - 4:00 pm CT
| Leader |
Jennifer Bellon, MD, FASTRO |
| Location |
Screen 30 |
| Abstracts |
Effectiveness and toxicity of re-irradiation after breast conserving surgery for recurrent breast cancer
Impact of thyroid gland volume on the risk of developing post-rt hypothyroidism in breast cancer patients requiring comprehensive nodal radiation
21 gene recurrence score to select patients with t3N0 ER+ breast cancer likely to benefit with postmastectomy radiation
Risk of radiation dermatitis in patients with skin of color who undergo radiation to the breast or chest wall irradiation and regional lymph nodes
|
| Leader |
Christin Knowlton, MD |
| Location |
Screen 16 |
| Abstracts |
Accelerated Partial Breast Irradiation vs. Intraoperative Radiation Therapy for Early Stage Breast Cancer and Ductal Carcinoma In Situ
Safety and Feasibility of Simultaneous Integrated Boost in Extreme 1-Week Hypofractionated Radiotherapy for Early Breast Cancer
Radiation-Induced Acute Cardiotoxicity in Women with Left Sided Breast Cancer: Results from a Phase II Prospective Clinical Trial
Association of Treatment Arm with Quantitative Cosmetic Outcome in a Randomized Trial Comparing Whole Breast Irradiation Dosing Schedules
|
| Leader |
Jose Bazan, MD |
| Location |
Screen 5 |
| Abstracts |
Are Diagnostic Computed Tomography Chest Scans Sufficient for Detecting Supraclavicular in Initial Breast Cancer Staging?
One-Year Toxicity of Ultrahypofractionated Breast Radiotherapy (+/- Sequential Boost) and a Survey of Patient Experience
Impact of Radiation Dosimetry and Clinical Factors on Implant-Based Breast Reconstruction Outcomes Following Post-Mastectomy Radiotherapy
Near-Maximum Rib Dose is the Most Relevant Risk Factor for Ipsilateral Spontaneous Rib Fracture: A Dosimetric Analysis of Breast Cancer Patients after Radiotherapy
Mediastinal and Hilar Lymphadenopathy Treated by SABR
|
Poster Walk 4: Biology
Monday, October 24, at 5:00 - 6:00 pm CT
| Leader |
Corey Speers, MD, PhD |
| Location |
Screen 13 |
| Abstracts |
An In Vivo CRISPR Screening Platform to Evaluate the Therapeutic Impact of DNA Damage Response Gene Mutations
Correlation between Edic vs. Components of the Immune System Using Whole Breast plus Lymph Nodes, Partial Breast, Hypo- and Conventionally Fractionated Prostate Radiation Therapy
Gold Nanoparticle (AuNP) as a Therapeutic Enhancer for Radio – And Immunotherapy Therapy Combination in Triple Negative Breast Cancer
Quantifying the Abscopal Effect in Breast Cancer Using Granzyme B PET Imaging
|
Poster Walk 5: Gastrointestinal Cancer
Tuesday, October 25, at 12:45 - 2:00 pm CT
| Leader |
Eric Miller, MD, PhD |
| Location |
Screen 6 |
| Abstracts |
Patient-Reported Bowel Function and Quality of Life Following Short and Long Course Radiotherapy for Locally Advanced Rectal Cancer
Necessity of External Iliac Lymph Nodes and Inguinal Nodes Radiation in Rectal Cancer with Anal Canal Involvement
Short-Course Radiotherapy Based Total Neoadjuvant Therapy Combined with Toripalimab for Locally Advanced Rectal Cancer: Preliminary Findings from a Randomized, Prospective, Multicenter, Double-Arm, Phase II Trial (TORCH)
The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008
Risk-Adjusted Chemoradiation according to Human Papilloma Virus Status for Anal Cancer: A Pilot Registry Study
|
| Leader |
Jeff Olsen, MD |
| Location |
Screen 22 |
| Abstracts |
Safety of Upfront Locoregional Therapy in Conjunction with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Response and Survival in Patients of BCLC Stage C Hepatocellular Carcinoma Receiving SBRT and Immunotherapy
Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer
Dosimetric Predictors of Acute and Late Gastrointestinal Toxicities in Stereotactic Online Adaptive Magnetic Resonance-Guided Radiotherapy (SMART) for Locally Advanced Pancreatic Adenocarcinoma
Using Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients with Pancreatic Cancer: A Multi-Institutional Safety and Feasibility Study
|
Poster Walk 6: Genitourinary Cancer
Tuesday, October 25, 2:30 - 3:45 pm CT
| Leader |
Mark Hurwitz, MD, FASTRO |
| Location |
Screen 2 |
| Abstracts |
Ten Year Follow-Up On 160 Patients Treated With Hypofractionated Prostate Salvage Radiation Therapy
Combined Brachytherapy and Ultra-Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Comparison of Toxicity Outcomes Using a High-Dose Rate (HDR) vs. Low-Dose Rate (LDR) Brachytherapy Boost
RTOG/NRG 1115 Quality of Life of Phase III Dose Escalated Radiation Therapy and Standard ADT with GnRH Agonist vs. Dose Escalated RT and ADT with GnRH Agonist and TAK-700
Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer
Toxicity Analysis of Patients with Prostate Cancer Treated with 3-D Conformal Compared to IMRT: Secondary Analysis of RTOG 0126 and RTOG 0415
|
| Leader |
Dabniel Hamstra, MD, PhD, FASTRO |
| Location |
Screen 30 |
| Abstracts |
The Maximum Standardized Uptake Value in Patients with Recurrent or Persistent Prostate Cancer after Radical Prostatectomy and PSMA-PET-Guided Salvage Radiotherapy – A Multicenter Retrospective Analysis
Randomized Trial of 18F-fluciclovine vs. 68Ga-PSMA PET/CT Guided Post-Prostatectomy Radiotherapy: Interim Volumetric and Toxicity Analyses
The Prognostic Value of the Size and the Sub-Site of the Local Failure at DCE-MRI before Salvage Radiotherapy for Prostate Cancer
The Accuracy of Multiparametric MRI in Identification of Intraprostatic Tumor Deposits after Local Prostate Radiation Therapy
Timing and Patterns of Potentially Salvageable Recurrences Following SBRT for Clinically Localized Prostate Cancer Assessed by Preferential Amino Acid Uptake
|
| Leader |
W. Robert Lee, MD, MS, MEd, FASTRO |
| Location |
Screen 13 |
| Abstracts |
Characterizing the Performance of a Deep-Learning Segmentation Algorithm for Outlining Dominant Intraprostatic Lesions on Prostate Multi-Parametric MRI
Acute and Late Toxicity of Prostate-Only or Pelvic SBRT in Prostate Cancer: A Comparative Study
ReIGNITE RT Boost: An International Study Testing the Feasibility, Accuracy and Reliability of Using Restriction Spectrum Imaging (RSI) MRI to Guide Radiotherapy Target Volume Delineation for Prostate Cancer Tumor Boost
Prostate Magnetic Resonance Imaging Delta-Radiomics during Image-Guided Conventional Fractionation and Stereotactic Ablative Radiotherapy
Single Fraction HDR Brachytherapy for Prostate Cancer: SiFEPI Phase II Trial Results
|
Poster Walk 7: Pediatric Cancer
Tuesday, October 25, at 5:15 - 6:15 pm CT
| Leader |
Luke Pater, MD |
| Location |
Screen 25 |
| Abstracts |
Multi-Institutional Investigation of Dose-Escalated Photon Radiotherapy for Intracranial Ependymoma
Dose Escalation for Posterior Fossa Ependymomas: Analysis of Prospective Pediatric Proton/Photon Consortium Registry
Incidence of Secondary Malignancy and Other Late Effects after Proton Radiotherapy for Retinoblastoma
Comprehensive Radiotherapy for Pediatric Ewing Sarcoma: Outcomes of a Prospective Proton Study
|
Poster Walk 8: Health Services Research
Wednesday, October 26, at 10:30 - 11:45 am CT
| Leader |
Fukimo Chino, MD |
| Location |
Screen 21 |
| Abstracts |
Cancer Mortality and the 2014 Medicaid Expansions under the Affordable Care Act
Price Variability of Standard Radiotherapy Procedure Codes in a Large Metropolitan Area from 2015-2021
Online Adaptive Radiotherapy and Opportunity Cost
Defining the Cost Variation by Site-of-Care for Radiotherapy: A Claims-Based Analysis
Value-Based Cancer Care: How are We Training Future Radiation Oncologists on the Quality/Cost Equation?
|
Poster Walk 9: Head and Neck Cancer
Wednesday, October 26, at 10:30 - 11:45 am CT
| Leader |
Henry Park, MD, MPH |
| Location |
Screen 8 |
| Abstracts |
The organs-at-risk dose constraints in head and neck intensity-modulated radiation therapy using data from a multi-institutional clinical trial (JCOG1015A1)
Chemotherapy and Radiation Dose Correlate with the Development of Hypothyroidism Following Radiation Therapy for Head and Neck Cancers
Prevalence and Functional Impact of Vertigo Among Long Term Survivors of Head and Neck Cancer
Surveillance With Electronic PROs and ctDNA in p16+ Oropharynx Cancer: Lessons From the Prospective FOCUS Registry (Follow up for HPV-related Oropharynx Cancer Concentrated on Symptom Change)
Development of Total Toxicity Burden Model in Head and Neck Cancer: Correlation of Clinician and Patient Reported Outcomes
|
Poster Walk 10: Physics
Wednesday, October 26, at 12:30 - 1:45 pm CT
| Leader |
Jerry Soen, MS, DABR, FACN |
| Location |
Screen 31 |
| Abstracts |
Real-World Dose Delivery Accuracy of Prostate SBRT with Tomotherapy Based Target Tracking
Clinical LINAC-Based Electron FLASH: Pathway for Practical Translation to Trials of FLASH Radiotherapy
Feasibility of Using a Deep Learning Auto-Segmentation Software Trained with Planning CT for Iterative CBCT Based Online Adaptive Prostate Treatment
Systematic Study of Patient-Specific Organs at Risk Auto-Segmentation on Daily kVCT Images for Adaptive Head and Neck Radiotherapy
Daily Artificial Intelligence-Assisted Adaptive Radiotherapy on Cone-Beam CT for Cancer of the Head and Neck
|